Cargando…
Current approaches to the management of Her2-negative metastatic breast cancer
While metastatic breast cancer (MBC) remains incurable, a vast array of active therapeutic agents has provided the opportunity for long-term disease control while maintaining quality of life and physical function. Optimal management of MBC balances a multitude of factors, including a woman's pe...
Autores principales: | Gogineni, Keerthi, DeMichele, Angela |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3446361/ https://www.ncbi.nlm.nih.gov/pubmed/22429313 http://dx.doi.org/10.1186/bcr3064 |
Ejemplares similares
-
A Review of Systemic Treatment in Metastatic Triple-Negative Breast Cancer
por: Zeichner, Simon B., et al.
Publicado: (2016) -
Quadruple-Negative Breast Cancer: An Uneven Playing Field
por: Saini, Geetanjali, et al.
Publicado: (2020) -
Quadruple-negative breast cancer: novel implications for a new disease
por: Bhattarai, Shristi, et al.
Publicado: (2020) -
Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+/HER2− metastatic breast cancer
por: Rugo, Hope S., et al.
Publicado: (2022) -
Current Landscape of Targeted Therapies for Hormone-Receptor Positive, HER2 Negative Metastatic Breast Cancer
por: Ballinger, Tarah J., et al.
Publicado: (2018)